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Prevention of long-term sickness absence and
major depression in high-risk employees: a
randomised controlled trial
Monique A S Lexis,1 Nicole W H Jansen,1 Marcus J H Huibers,2
Ludovic G P M van Amelsvoort,1 Ate Berkouwer,3 Gladys Tjin A Ton,3
Piet A van den Brandt,1 IJmert Kant1
ABSTRACT
Objectives To examine the efficacy of early intervention
on the prevention of long-term sickness absence and
major depression among employees at high risk of future
sickness absence and with mild to severe depressive
complaints.
Methods Randomised controlled trial conducted among
employees working in an office environment. 139
employees were identified both at high risk of future
sickness absence and with mild to severe depressive
complaints through screening. Subsequently, they were
randomly assigned to the intervention group (n¼69) or
the control group (n¼70). Objective sickness absence
was analysed at 12 and 18 months of follow-up.
Depressive complaints were assessed by the Beck
Depression Inventory (BDI-II) at baseline, and at 6 and
12 months of follow-up.
Results Intention-to-treat analyses showed a significant
difference in total sickness absence duration between
the intervention (27.5 calendar days (SD 44.7)) and
control group (50.8 days (SD 75.8)) over 12 months of
follow-up, a reduction of 46% (p¼0.017). The
intervention group showed a non-significantly lower
proportion of long-term sickness absence spells
compared with the control group (p¼0.127). Statistically
significant and clinically relevant differences in
depressive complaints were found after both 6 months
(p¼0.001) and 12 months (p¼0.005) of follow-up, in
favour of the intervention group. Relative risk reductions
(RRR) were 19.2% and 19.8% respectively. Sickness
absence data were available for all participants over
18 months of follow-up. Questionnaire data were
available for 99 (at 6 months) and 90 participants (at
12 months). No adverse events or side effects occurred.
Conclusions Early intervention in employees with mild
to severe depressive complaints and high risk of future
long-term sickness absence proved to be effective in
preventing/reducing both sickness absence and
depressive complaints.
INTRODUCTION
Mental health problems are highly prevalent in the
labour force and constitute a source of marked
distress and social impairment for the employee.1 2
Major depression is considered to be one of the more
severe disorders, making up a substantial part of the
mental health problems.3 Recent studies showed
that depressive complaints are also prevalent in the
workingpopulation on a relativelymild level.4 5Over
time, these depressive complaints may exacerbate
and result in major depression.6 Depressive
complaints are found to be often associated with
work disability and long-term sickness absence and
increased healthcare use.7 8 Work disability and
especially long-term sickness absence have also
increasingly been recognised as considerable public
health problems, with consequences for employers
and society.9 So far, work rehabilitation in case of
sickness absence due to mental health complaints
remains very difﬁcult, and symptom reduction does
not necessarily lead to work resumption.10 11
Conversely, sickness absence can cause and predict
depressive complaints.12 13
From an occupational healthcare perspective,
before treating employees with major depression or
treatment of employees who are already on sick
leave, a preventive strategy aimed at prevention of
major depression and long-term sickness absence
through early intervention might be more effective.
A prerequisite for such a strategy is the ability to
identify employees at high risk of future long-term
sickness absence and with mild depressive
complaints. To identify employees at high risk of
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What this paper adds
< Work rehabilitation in case of sickness absence
due to mental health complaints remains very
difficult, and symptom reduction does not
necessarily lead to work resumption.
< A previous study on a preventive strategy aimed
at early intervention among employees identified
at high risk of future sickness absence proved
effective in the prevention of long-term sickness
absence.
< Depressive complaints are highly prevalent in
the working population and are associated with
future long-term sickness absence.
< Preventive intervention among employees iden-
tified both at high risk of future sickness
absence and with mild to severe depressive
complaints proved effective in the prevention/
reduction of long-term sickness absence and
depressive complaints.
< The next step will be further implementation of
the preventive strategy in the occupational
health setting.
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sickness absence, a screening questionnaire, called Balansmeter
in Dutch, was developed in 1998.14 The Balansmeter proved to
have good properties in predicting long-term sickness absence. In
an additional study by Kant et al5 conducted in 2003, it was
demonstrated that early intervention among employees at risk
of sickness absence proved effective in reducing future sickness
absence. The current study, including a new RCT, focused on
both high risk of sickness absence and depressive complaints. It
was hypothesised that early intervention is effective in
preventing depressive complaints and/or future sickness
absence.
Numerous studies have investigated the effectiveness of
different treatments for depression.15 16 Strong evidence exists
that cognitive behavioural therapy (CBT) and problem-solving
therapy (PST) are effective treatments for depression.17e20 CBT
and PST have also been proven effective in reducing sickness
absence.21 22 A new protocol speciﬁcally targeted at employees,
who are identiﬁed both at high risk of sickness absence and with
mild to severe depressive complaints, was developed based on
CBT and PST, with the main focus on work-related problems.
The aim of this RCT is to examine the efﬁcacy of this new
protocol among employees identiﬁed at high risk of long-term
sickness absence and with mild to severe depressive complaints
on the prevention of future long-term sickness absence and
major depression.
METHODS
Study design, procedure and participants
A randomised controlled trial (RCT) was conducted among
employees of a large banking company in The Netherlands.
Figure 1 presents the selection process of the study. In 2007,
23 973 employees received a screening questionnaire at their
home address. In the invitation letter, employees were asked to
provide written informed consent, which covered the usage of
questionnaire data, the company data on sickness absence and
the possibility of participating in the trial. In total, 9157
employees (38.2%) responded to the questionnaire; 8892 ques-
tionnaires were suitable for analyses, and 265 were discarded due
to technical reasons or because no informed consent was
provided. Employees identiﬁed at risk of sickness absence and
with mild to severe depressive complaints (n¼211) received an
extensive baseline questionnaire (T0). Exclusion criteria were
being (fully or partially) absent from work, pregnant or on
pregnancy/maternity leave or receiving treatment by a psychol-
ogist/psychiatrist, at the time of completing the screening
questionnaire. Employees who responded to the baseline ques-
tionnaire (n¼150) and still met the selection criteria (n¼139)
were randomised into the intervention (n¼69) or the control
group (n¼70). Randomisation sequences were generated using
computerised random number generators (block size 2) by the
principal investigator (ML), based on employee personnel
numbers. Company counsellors and psychologists were not
blind to group allocation. However, they were only aware of
participants of the intervention group. Follow-up questionnaires
were sent at 6 and 12 months after randomisation to assess
depressive complaints and secondary outcomes. Objective sick-
ness absence data were assessed at 12 and 18 months of follow-up.
The study was covered by the medical guidelines of the occu-
pational health service, thereby ensuring all participants’ privacy
and anonymity. The study was approved by the Medical and
Ethical Committee of Maastricht University (MEC 06-3-018).
The study was performed according to the Declaration of
Helsinki.
Preventive intervention
The intervention consisted of a psychological treatment based on
the principles of PSTand CBT. The main goal of the intervention,
which had an individual orientated approach, was to offer
guidelines to enhance problem-solving skills in order to prevent
long-term sickness absence and to reduce depressive complaints
and to stimulate personal well-being. The intervention was
speciﬁcally developed for our target population by four experts in
the ﬁeld of psychology. A treatment protocol and workbooks for
practical assignments were developed for the trial based on two
main sources.23e26 The focus of the protocol was on employees
with relatively mild complaints and who were still at work. The
intervention was preventive because of its timing, treatment
before sickness absence occurs and because it focused on relatively
mild complaints. Therefore, the intervention consisted largely of
PST. CBT/PSToften consist of 10 to 12 sessions. This new inter-
vention consisted of a basic part and a speciﬁc part. The basic part
contained seven sessions of 45 min each, based on themajor steps
of PST. Through all sessions, principles of CBTwere applied. The
seventh session consisted of an evaluation session. Since it was
unknown at the start of the study if seven sessions would be
sufﬁcient for every participant, the intervention could be
extendedwith amaximumof ﬁve sessions. In the seventh session,
the psychologist and employee decided in consultation to end
treatment in case the participant had recovered or to move on
with the speciﬁc part of the protocol. For the speciﬁc part, the
employee could indicate the subject to focus on during the
sessions, such as training of social skills or cognitive restructuring.
At the end of each session, homework assignments were given
which were discussed in the next session. The intervention was
conducted by 10 psychologists from a company consisting of
a nationwide network of registered psychologists (Cenzo BV).
This company regularly provides psychological healthcare for the
banking company. The psychologists received 2 days of training
before the study started and a 1-day booster session during the
study. Participants in the control group received care as usual from
the occupational health services. Care as usualwhen the employee
asks for help included consultation with an occupational physi-
cian and, if necessary, referral to other disciplines. Care as usual in
case of sickness absence included social medical counselling.
Measurements
Screening measures
Risk of sickness absence
The Balansmeter, developed in 1998 for employees working in
an ofﬁce work environment, was used to identify employees at
high risk for future long-term sickness absence. The Balansmeter
was developed and internally validated on data of the Maas-
tricht Cohort Study and was externally validated in 2003 on
a large sample of employees of the same company at which the
current RCT was conducted.14 For the present study, a cut-off
point with 87.9% speciﬁcity and 52.6% sensitivity in women
and 87.8% and 65.1% in men was applied.
The BM includes risk of sickness absence in general, not
necessarily due to depressive complaints. A second measure was
included to assess depressive complaints.
Depressive complaints
Presence and severity of depressive complaints were assessed
using the depression scale of the Hospital Anxiety and Depres-
sion Scale (HAD Scale). The HAD Scale is a 14-item self-report
questionnaire, which was originally developed to indicate the
presence and severity of both anxiety (HAD-A) and depression
(HAD-D) separately.27 28 With respect to the cut-off values, we
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used the values suggested by Zigmond et al.28 A higher score on
HAD-D indicates more severe depressive complaints. Employees
were deﬁned as having mild to severe depressive complaints
when they scored 8 points or higher on HAD-D.
Primary outcome measures
Sickness absence duration
Sickness absence duration was measured objectively (in calendar
days) through record linkage on an individual level with the
company registers on certiﬁed sickness absence from 2 months
after employees received the screening questionnaire until
18 months of follow-up. Long-term sickness absence was deﬁned
as a sickness absence spell lasting for more than 28 consecutive
days. Sickness absence was assessed for 12 and 18 months of
follow-up. Measurement of sickness absence started 2 months
after completing the screening questionnaire. This is in line with
the development of the Balansmeter.14 Returning and processing
of the questionnaires could at most take 2 months.
Depressive complaints
Depressive complaints are viewed as a continuous spectrum of
complaints, ranging from no to severe depressive complaints,
with major depression at the end of the spectrum. While the
screening instrument included theHADScale, to assess severity of
depressive complaints more extensively the commonly used Beck
Depression Inventory-II (BDI-II) was used.29 For our focus on
relatively mild complaints, the BDI-II was too extensive and
included too ‘heavy ’ items, on for example suicidal thoughts, to
include in the screening questionnaire. We therefore included the
BDI-II in the baseline questionnaire and at 6 and 12 months of
follow-up. Scores on the BDI-II can range from 0 to 63, with
higher scores indicating more severe depressive symptoms.30
Scores from 0 to 13 points were deﬁned as not/minimally
depressed, 14e19 points as possibly/lightly depressed, 20e28 as
moderately depressed and 29e63 points as severely depressed.29 31
Secondary outcome measures
Data on secondary outcome measures were gathered by means
of self-administered questionnaires at baseline, and at 6 and
12 months of follow-up.
Self-rated health
Self-rated health was assessed with one item from the Short
Form Health Survey (SF-36), widely used to measure general
Figure 1 Flow diagram of recruitment,
allocation and outcome assessment.
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health status.32 33 ‘In general, would you say your health is’.
This item was scored on a ﬁve-point scale (1¼excellent, 2¼very
good, 3¼good, 4¼moderate, 5¼bad). The Brief Symptom
Inventory (BSI), a short version of the Symptom Checklist 90
(SCL-90), was used to measure general psychological distress,
with higher scores indicating a higher degree of symptoms
(range 0e212).34 35 Scores on HAD-D at 6 and 12 months of
follow-up were deﬁned as a secondary outcome measure.
Work characteristics
A validated Dutch version of the Job Content Questionnaire was
used to measure psychological job demands, decision latitude
and social support at work.36 Additional data on job insecurity
and commitment were gathered with questions adapted from
the Questionnaire on the Experience and Evaluation of Work
(VBBA).37
Cointerventions
Cointerventions in the past 6 months, such as treatment by
a general practitioner, an occupational physician, a psychologist,
a psychiatrist or a company counsellor and the use of medication
(including antidepressants, sleeping medication, tranquillisers,
painkillers or other) were assessed by self-report.
Treatment adherence
For each participant in the intervention group, it was assessed
whether the intervention was conducted according to the
protocol. Adherence to the protocol was deﬁned as being
exposed to all essential predeﬁned steps of the intervention. For
the per-protocol analyses, those participants who received at
least one treatment session were included, which is a rather
conservative approach.
Power calculation
In calculating sample size, sickness absence was chosen as the
main outcome measure of the study. Based on sickness absence
data from the Maastricht Cohort Study on fatigue at work, it
appeared that 60% of employees with psychological complaints
were absent from work for at least 2 weeks over a period of
12 months of follow-up.2 The assumption was that the inter-
vention would be effective by reducing this percentage to 35%.
Power calculation, using a two-sided signiﬁcance level of 5% and
a power of 80%, indicated a minimum of 59 participants in each
group. Taking into account a potential attrition of 15%, a ﬁnal
sample size of 136 should be sufﬁcient.
Statistical analysis
First, data were analysed according to the intention-to-treat
principle. Difference scores on continuous outcomes were used
for both sickness absence (0e12 months and 0e18 months) and
depressive complaints (T0eT1 and T0eT2). To estimate the
efﬁcacy of the intervention, Poisson regression analysis was used
for the outcomes sickness absence duration and sickness absence
frequency. Risk ratios were calculated for dichotomous
outcomes. Linear regression analysis was used for continuous
outcomes, adjusted for baseline differences. Multivariate Cox
regression analysis was used to test differences in time to onset
of the ﬁrst sickness absence spell. Clinically meaningful changes
on the BDI-II were determined by calculating the Reliable
Change Index as developed by Jacobson and Truax.38 This
approach is based on two components: reliable change, that is
a decrease of at least 7 points; and clinically signiﬁcant change,
that is post-treatment score below 14.29 31 Chi-square tests were
used to test frequency differences in reliable and clinically
signiﬁcant change.
Second, for the per-protocol analyses, outcomes were
compared between those employees who received at least one
treatment session and the control group.
All analyses were performed using SPSS version 15.0, Stata
statistical software package 8.0 and SAS.
RESULTS
Participants
Figure 1 presents a ﬂow chart of the study. Recruitment started
in February 2007 and was completed in October 2007. A total of
139 employees were enrolled in the trial and randomised into the
intervention group (n¼69) or the control group (n¼70). At 6 and
12 months of follow-up, questionnaire data were available for 99
and 89 participants respectively. Objective sickness absence data
were available for all participants for 18 months of follow-up.
The baseline characteristics of the trial population are listed in
table 1. Except for BDI and BSI, baseline characteristics were
comparable between the intervention and control group.
Effects of the intervention on the primary outcomes sickness
absence duration and depressive complaints
Table 2 presents the results of the intention-to-treat analysis for
the primary outcome measures sickness absence duration at 12
and 18 months of follow-up and depressive complaints at 6 and
12 months of follow-up. A signiﬁcant difference in total sickness
absence duration was found between the intervention
(27.5 days) and control group (50.8 days) at 12 months of
follow-up, a reduction of 46% (p¼0.017). The intervention
group showed a non-signiﬁcantly lower proportion of long-term
sickness absence spells (nine of 69) compared with the control
group (17 of 70) (p¼0.127) at 12 months of follow-up. At
18 months of follow-up, the total sickness absence duration was
45.0 days in the intervention group and 62.6 days in the control
group, a reduction of 28.0%. However, this result failed to reach
statistical signiﬁcance (p¼0.150). No signiﬁcant difference was
found in the proportion of long-term sickness absence as well
(p¼0.175). Regarding depressive complaints, signiﬁcant differ-
ences in change scores were observed for both T1eT0 (p¼0.001)
and T2eT0 (p¼0.005) between the intervention and control
Table 1 Baseline characteristics of the trial population
Variable
Intervention
group (n[69)
Control
group (n[70)
Gender, male; N (%) 42 (60.9) 43 (61.4)
Age (18e65); mean (SD) 48.41 (8.68) 47.07 (9.49)
Highest level of education; N (%)*
Low 5 (7.9) 6 (9.0)
Medium 49 (77.8) 45 (67.2)
High 9 (14.3) 16 (23.9)
Presence of long-term illness; N (%)y 39 (59.1) 34 (51.5)
Living alone; N (%)y 12 (17.4) 13 (18.6)
Depressive complaints (Hospital Anxiety
and Depression ScaledDepression)
(0e21)z; mean (SD)
10.45 (2.67) 9.97 (2.34)
Depressive complaints (Beck Depression
Inventory-II) (0e63)z; mean (SD)
17.03 (9.56) 14.84 (8.11)
Psychological distress (Brief Symptom
Inventory) (0e212)z; mean (SD)
40.79 (27.85) 35.34 (25.47)
Score on Balansmeter (indicating risk of
sickness absence); mean (SD)
e0.5902 (0.9599) e0.5993 (0.7562)
Working hours/week; mean (SD) 34.8 (4.52) 34.9 (4.91)
Having an executive position; N (%)y 4 (5.8) 7 (10.0)
*Categorical variable with N (%) indicating ‘yes.’
yDichotomous variable (yes/no) with N (%) indicating ‘yes.’
zScale range.
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group, in favour of the intervention group. Depressive
complaints decreased in the intervention group during follow-up
and increased in the control group. The intervention group
showed a signiﬁcantly higher proportion of participants with
a reliable change in depressive complaints (15 of 43) versus the
control group (8 of 51) at 6 (p¼0.031) and 12 months (p¼0.022)
of follow-up (proportion reliable change in the intervention
group 13 of 42, in the control group 5 of 45). RRR were 19.2%
and 19.8%, NNTwere 5.2 (95% CI 2.7 to 55.5) and 5.0 (95% CI
2.7 to 32.1) respectively, for 6 and 12 months of follow-up. The
proportion of clinically relevant change in the intervention
group was 27 of 44 versus 26 of 53 in the control group at
6 months of follow-up (p¼0.225). At 12 months, the clinically
relevant change in the intervention group was 28 of 43 and 20 of
45 in the control group (p¼0.052).
Effects of the intervention on secondary outcomes
Table 2 also presents the results of the intention-to-treat analysis
for the secondary outcomes. Comparable with the results on
BDI-II, statistically signiﬁcant differences in change scores on
HAD-D were found in favour of the intervention group,
between T1eT0 and T2eT0. Signiﬁcant differences were found
for change scores for T1eT0 and T2eT0 on BSI as well. Again,
scores decreased in the intervention group and increased in the
control group. No signiﬁcant differences were found between
T1eT0 and T2eT0 between both groups on self-rated health
and work characteristics (results not shown).
Per-protocol analysis
Table 3 presents the results of the per-protocol analyses. Sickness
absence and depressive complaints were compared between the
intervention group, including those employees who received at
least one session, and the control group. The intervention group
demonstrated a signiﬁcantly lower sickness absence duration of
52.2% after 12 months (p¼0.021) and 47.1% after 18 months
(p¼0.021) compared with the control group. The latter result of
sickness absence duration at 18 months of follow-up differs with
the result of the intention-to-treat analysis, in which a non-
signiﬁcant reduction of 28.0% was found. No signiﬁcant differ-
ence was found for the proportion of sickness absence spells
>28 days at 12 months (p¼0.160) and 18 months (p¼0.078) of
follow-up. Regarding depressive complaints, similar to the
Table 2 Outcomes of the intention-to-treat analysis, with objective sickness absence measured at 12 months and 18 months of follow-up and
questionnaire data measured at baseline (T0), 6 months (T1) and 12 months (T2) of follow-up.
Variable Intervention group (n[69) Control group (n[70) b, RR, HRx (95% CI) p Value
Objective sickness absence
0e12*
At least one time on sick leave; N (%)z 56 (81.2) 48 (68.6) 1.18 (0.97 to 1.44) 0.118
Duration (calendar days); mean (SD)/
median
27.48 (44.74)/11.00 50.83 (75.75)/15.00 0.62 (1.12 to 0.11) 0.017
Frequency; mean (SD)/median 2.34 (1.61)/2.00 2.35 (1.78)/2.00 0.01 (0.28 to 0.26) 0.963
Time to onset of first sickness absence
spell (calendar days); mean (SD)
151.38 (136.99) 187.37 (146.42) 1.35 (0.92 to 1.99) 0.129
0e18y
At least one time on sick leave; N (%)z 62 (89.9) 56 (80.0) 1.12 (0.98 to 1.29) 0.154
Duration (calendar days); mean (SD)/
median
45.03 (76.59)/20.50 62.57 (81.89)/25.50 0.33 (0.78 to 0.12) 0.150
Frequency; mean (SD)/median 2.97 (2.09)/2.00 2.93 (2.17)/2.00 0.01 (0.24 to 0.67) 0.918
Time to onset of first sickness absence
spell (calendar days); mean (SD)
177.87 (184.21) 231.19 (206.57) 1.34 (0.93 to 1.93) 0.117
Participants with sickness absence spell(s) >28 calendar days; N (%)z
0e12* 9 (13.0) 17 (24.6) 0.54 (0.26 to 1.12) 0.127
0e18y 14 (20.3) 22 (31.4) 0.65 (0.36 to 1.16) 0.175
Depressive complaints according to Beck Depression Inventory-II (0e63){; mean (SD)
Baseline T0 17.03 (9.55) 14.84 (8.11)
T1 12.77 (10.48) 16.30 (10.08)
T2 12.42 (9.64) 16.69 (11.04)
T1eT0 4.41 (7.00) 0.92 (7.06) 5.08 (7.91 to 2.25) 0.001
T2eT0 3.79 (8.45) 2.09 (9.51) 5.40 (9.12 to 1.68) 0.005
Depressive complaints according to Hospital Anxiety and Depression ScaledDepression (0e21){; mean (SD)
Screening 10.45 (2.67) 9.97 (2.34)
T1 7.67 (4.26) 8.55 (3.81)
T2 7.24 (4.62) 9.40 (4.23)
T1-screening 2.91 (3.67) 1.45 (3.06) 1.38 (2.74 to 0.02) 0.046
T2-screening 3.24 (4.50) 0.38 (3.91) 2.62 (4.41 to 0.83) 0.005
Psychological distress (Brief Symptom Inventory) (0e212){; mean (SD)
Baseline 40.79 (27.85) 35.34 (25.47)
T1 32.26 (30.84) 36.89 (29.43)
T2 32.19 (33.29) 42.19 (33.78)
T1eT0 9.71 (18.12) 4.55 (17.33) 13.88 (21.72 to 6.04) 0.001
T2eT0 9.32 (25.39) 6.51(15.69) 15.69 (25.11 to 6.26) 0.001
*Measured from baseline until 12 months of follow-up.
yMeasured from baseline until 18 months of follow-up.
zDichotomous variable (no/yes) with N (%) indicating ‘yes.’
xb (95% CI) in case of continuous variable, RR (95% CI) in case of dichotomous variable and HR in case of time to onset of first sickness absence spell.
{Scale range.
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results of the intention-to-treat analysis, statistically signiﬁcant
lower scores on BDI-II were found between T1eT0 (p¼0.004)
and T2eT0 (p¼0.006) in the intervention group. HAD-D also
showed signiﬁcantly lower scores at T2-Screening in the inter-
vention group, and for BSI signiﬁcant differences were found
between both T1eT0 and T2eT0 (results not shown).
Treatment received and cointerventions
Of the 69 employees allocated to the intervention group, 38
employees completed the intervention and returned their
workbooks. The mean number of sessions was 7.5 (SD 2.5). The
mean protocol adherence of the psychologists was 95% (SD
12.6). With respect to the use of cointerventions (table 4) only
a small number of employees received cointerventions speciﬁ-
cally for depressive complaints. No signiﬁcant and clinically
relevant differences were found between the intervention and
control group at baseline, 6 and 12 months of follow-up in their
use of cointerventions.
DISCUSSION
Principal findings and interpretation of outcomes
The aim of this study was to evaluate the effect of a preventive
intervention among employees identiﬁed at high risk of future
long-term sickness absence and with mild to severe depressive
complaints in a RCT. The preventive intervention had
a substantial effect on sickness absence duration and depressive
complaints in favour of the intervention group. During the years
in which this study was conducted, sickness absence rates in the
company under study were 3.83% (in 2007) and 3.77% (in 2008).
Sickness absence rates were 13.93% in the control group and
7.53% in the intervention group over 12 months of follow-up,
which indicates that indeed a high-risk group was selected.
Although sickness absence was substantially lower in the
intervention group than in the control group, the sickness
absence rates of the company could not be reached during the
follow-up of 18 months. The proportion of long-term sickness
absence spells showed no signiﬁcant difference between the
intervention and control group, despite a reduction of 40% as
described in the power calculation. This may be explained by the
decrease in sickness absence rates in The Netherlands, from
approximately 6.0% in 1999, the year in which the power
calculation was conducted, to 4.3% in 2009. Results may have
failed to reach statistical signiﬁcance due to the lower prevalence
of sickness absence in the population. Sickness absence
frequency and time to onset of the ﬁrst sickness absence spell
may have been inﬂuenced by the intervention as well, but no
signiﬁcant differences were found between the groups, which
may have been because the power was too low.
Table 3 Outcomes of the per-protocol analysis, objective sickness absence measured at 12 and 18 months of follow-up and questionnaire data
measured at baseline (T0), 6 (T1) and 12 months (T2) of follow-up.
Variable
Intervention group, ‘never started’
group excluded (n[46) Control group (n[70) b, RR, HRx (95% CI) p Value
Objective sickness absence 0e12*
At least once on sick leave (N, %)z 34 (73.9) 48 (68.6) 1.08 (0.85 to 1.36) 0.677
Duration (calendar days); mean (SD)/
median
24.29 (34.18)/11.00 50.83 (75.75)/15.00 0.74 (1.37 to 0.11) 0.021
Frequency; mean (SD)/median 2.18 (1.47)/2.00 2.35 (1.78)/2.00 0.08 (0.39 to 0.23) 0.621
Time to onset of first sickness absence
spell (calendar days); mean (SD)
165.67 (143.77) 187.37 (146.42) 1.18 (0.76 to 1.82) 0.473
0e18y
At least one time on sick leave (N, %)z 39 (84.8) 56 (80.0) 1.06 (0.89 to 1.26) 0.625
Duration (calendar days); mean (SD)/
median
33.05 (51.18)/15.00 62.57 (81.89)/25.50 0.64 (1.18 to 0.10) 0.021
Frequency; mean (SD)/median 2.69 (1.89)/2.00 2.93 (2.17)/2.00 0.08 (0.37 to 0.20) 0.569
Time to onset of first sickness absence
spell (calendar days); mean (SD)
200.76 (198.97) 231.19 (206.57) 1.18 (0.78 to 1.77) 0.441
Participants with sickness absence spell >28 calendar days; N (%)z
0e12* 6 (13.0) 17 (24.3) 0.54 (0.23 to 1.26) 0.160
0e18y 7 (15.2) 22 (31.4) 0.48 (0.23 to 1.04) 0.078
Depressive complaints according to Beck Depression Inventory-II (0e63){; Mean (SD)
Baseline T0 18.15 (9.42) 14.84 (8.11)
T1 14.00 (11.50) 16.30 (10.08)
T2 12.31 (10.01) 16.69 (11.04)
T1eT0 e4.50 (7.59) 0.93 (7.06) 5.02 (8.34 to 1.70) 0.004
T2eT0 e4.66 (8.76) 2.09 (9.51) 6.05 (10.34 to 1.75) 0.006
*Measured from baseline until 12 months of follow-up.
yMeasured from baseline until 18 months of follow-up.
zDichotomous variable (no/yes) with N (%) indicating ‘yes.’
xb (95% CI) in case of continuous variable and RR (95% CI) in case of dichotomous variable and HR in case of time to onset of first sickness absence spell.
{Scale range.
Table 4 Cointerventions used 6 months before completing
questionnaires T1 and T2
Variable
Intervention
group (n[69)
Control
group (n[70) p Value
Cointerventions*; N (%)
At T1 35 (77.8) 35 (64.8) 0.158
At T2 31 (72.1) 33 (70.2) 0.960
Receiving treatment for depressive complaints (not our intervention); N (%)
At T1 2 (4.4) 7 (13.0) 0.142
At T2 5 (11.6) 4 (8.5) 0.644
Medication use; N (%)
At T1 33 (73.3) 35 (64.8) 0.363
At T2 27 (62.8) 27 (57.4) 0.788
*Treatment by general practitioner, occupational physician, psychologist, psychiatrist,
company counsellor or other.
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With regard to depressive complaints (BDI-II), substantial
effects were found in the intention-to-treat analysis, again in
favour of the intervention group. Scores on BDI-II increased over
time in the control group and decreased in the intervention
group. Participants in the intervention and control group did not
differ in their use of cointerventions. Cointerventions were not
likely to have inﬂuenced the results, but this could not be
completely ruled out. Cointerventions might have reduced the
contrast between the groups, and this might have led to an
underestimation of the effects found.
Regarding the per-protocol analysis, sickness absence duration
was signiﬁcantly lower in the intervention group at 12 months
but also at 18 months. These results indicate that when
participants received at least one session, the reduction of sick-
ness absence duration remained approximately 50% until
18 months of follow-up. Regarding depressive complaints,
similar results to the intention-to-treat analysis were found.
Again, scores on BDI-II increased in the control group and
decreased in the intervention group over time. Thus, these
results demonstrate that even a small number of sessions seems
to be effective. For the per-protocol analysis, a rather conserva-
tive approach was used, which also indicates that our results
may be an underestimation.
Methodological considerations
Strengths of the study include the randomised design, the
availability of a nationwide study population of employees, the
objective measurement of sickness absence, the intervention for
which a speciﬁc protocol was developed, the long follow-up
period of 18 months and the monitoring of cointerventions.
Some considerations should be taken into account when
interpreting the results of the study. During the pilot study
conducted prior to the RCT, a smaller-than-expected overlap
between the concepts of risk for future sickness absence and
depressive complaints was found. To guarantee sufﬁcient
numbers of participants, two adjustments to the original study
design were required. First, the screening questionnaire was sent
to more employees than originally planned. Second, the cut-off
point on the Balansmeter was adapted to a cut-off point with
a higher sensitivity to improve the overlap between the
concepts. The original cut-off point on the HAD-D was main-
tained, since this cut-off point has been used in many studies.
The smaller-than-expected overlap between both concepts may
be explained by differences in the background of the concepts.
Risk of sickness absence has a multifactorial aetiology, which
does not necessarily include health complaints.
The HAD-D was used to identify employees with mild to
severe depressive complaints. To study the course of depressive
complaints, the more widely used and more extensive ques-
tionnaire BDI-II was used. Our results indicate that many of
those employees identiﬁed with mild to severe depressive
complaints by HAD-D (48.2%) scored in the no to minimal
depressive complaints range of the BDI-II at baseline. The mean
BDI-II score was 9.77 (SD 3.35) in this category. Regardless of
the relatively low score of the employees identiﬁed, scores were
still in the upper part of the lowest category of BDI-II (range
0e13). So, a reliable and relevant change on BDI-II (>7 points)
could still occur.
With regard to blinding, the researcher analysed all data
anonymously using personnel numbers. Participants in the RCT
were not blinded, since they were aware into which group they
were randomised. However, little inﬂuence on the results was
expected, since no differences in the use of cointerventions were
observed. Company counsellors and psychologists were partially
blinded, as they were only aware of participants in the inter-
vention group. Therefore, no inﬂuence on the contrast between
the intervention- and control group was expected. Incomplete
blinding may have had some inﬂuence on the outcome depres-
sive complaints and the secondary outcomes. However, sickness
absence was measured objectively and blinded for the researcher
and could therefore not have inﬂuenced the results.
Only 38 employees of the 69 employees who were randomised
into the intervention group received the intervention according
to protocol, implying 44.9% incomplete interventions. A with-
drawal rate of 35.3% was found on the questionnaires at
12 months of follow-up. Drop-outs and loss-to-follow-up in the
intervention group could have affected the results. However,
since objective sickness absence data were available for all 139
randomised employees, there were no consequences for this
outcome. For depressive complaints, no selective attrition was
found, and no differences in baseline values on BDI-II were
found between respondents and non-respondents on T1 and T2.
The high number of employees dropping out after consultation
with the company counsellor may be explained by the fact that
the focus of the RCT was on relatively mild depressive
complaints and an increased risk for a future event. Many
employees reported not to experience health complaints at the
moment of completing the screening questionnaire and there-
fore may have refused participation.39
Implications and future research
This study focused on prevention of sickness absence and major
depression; however prevention will never completely compen-
sate treatment, since there will always be employees who will
develop a clinical depression, who have depressive complaints
but do not lose their work ability, who will go on sick leave or
who do not beneﬁt from preventive intervention. As a result,
treatment remains very important.
The focus of our RCTwas on employees with relatively mild
depressive complaints. Within this mild level, complaints vary in
severity. Our results demonstrated that 17 of the 46 employees
who started participation in the intervention received fewer
than seven sessions of the basic part of the intervention. From
a research perspective, it was preferable to indicate a ﬁxed
number of sessions the participants should receive in the inter-
vention, to be able to exactly deﬁne completion of the inter-
vention. However, in practice this approach was not feasible,
since it was unknown how many sessions were required for the
mild level of complaints. The per-protocol analysis showed that
receiving even a small number of sessions seems already effec-
tive. This may indicate that the intervention should be tailored
to an employee’s individual level of complaints.
The efﬁcacy of the preventive intervention was evaluated
among employees in an ofﬁce work environment. Therefore, this
study is not fully representative for the general working popu-
lation. Nevertheless, it is believed that the intervention may be
suitable for similar companies in the occupational healthcare
setting, because of the occurrence of comparable kinds of
complaints/problems, characterised by stress-related (mental)
disorders.
When considering implementation of the preventive strategy
into daily practice, employers and policymakers should weigh
the effects against the costs of the intervention. Evaluation of
the cost-effectiveness was not part of the study. However, based
on the intention-to-treat analysis, a decrease of 555 working
days of sickness absence between the intervention and control
groups was calculated over 18 months of follow-up. The mean
labour costs account for €200 per working day. Thus, the proﬁts
406 Occup Environ Med 2011;68:400e407. doi:10.1136/oem.2010.057877
Original article
 group.bmj.com on April 17, 2012 - Published by oem.bmj.comDownloaded from 
of reduction of sickness absence amounted to €111 000. Besides
beneﬁts in terms of money due to sickness absence, it is known
that depression is associated not only with absenteeism but also
with presenteeism.40 The positive effect of the intervention on
depressive complaints may lead to increased at-work job
performance and productivity. In future research, a more
extensive costebeneﬁt analysis should be performed including
all facets of the preventive strategy.
In conclusion, the results of this study showed strong
preventive effects on both long-term sickness absence and major
depression. In the light of the difﬁcult return to work in
employees who are already on sick leave, this study clearly
demonstrated that a new preventive intervention is a more
promising approach in the prevention and reduction of sickness
absence and improvement of mental health among employees.
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